Abstract
INTRODUCTION
Chronic rhinosinusitis (with or without nasal polyps) is a common otolaryngologic disease worldwide. The management options for sinonasal polyposis are medication, surgery, or both. Surgical intervention in the treatment of chronic rhinosinusitis (CRS) is considered in patients who fail to improve after a trial of medical treatment for three months. Endoscopic sinus surgery significantly improves the quality of life of patients with chronic rhinosinusitis. 1 Currently, functional endoscopic sinus surgery (FESS) is the standard treatment for CRS, based on the principle established by Messerklinger, who recommended restoring the natural function of the sinuses.
2 FESS involves clearing polyps and inflammatory tissue and opening the sinus ostia. However, up to 25% of patients with adhesions will require revision surgery. 3 It is common practice to use a topical agent with intranasal corticosteroids (INC) as the first therapeutic choice, followed by surgery. There is good evidence from randomized controlled trials that supports the use of topical nasal corticosteroids to improve endoscopic polyp and symptom scores and reduce the recurrence of polyps. 4 Traditional Chinese herbal medicine (TCM) is also being increasingly used for the treatment of CRS. [5] [6] [7] A systematic review has shown that the effects of herbal medicines in the treatment of rhinosinusitis are limited -in particular, for CRS. 8 But, it opined that postoperative treatment is an interesting area for future studies on this topic. A randomized, double-blind, placebo-controlled study reported no significant benefit of Tsang-Erh-San extract granules, Houttuynia extract powder, or oral amoxicillin in the post-FESS care of CRS patients. Most of the studies above used single herbs or their extracts. Based on practices in China and East Asia, the essence of CHM is an herbal formulation that can balance "Yin-Yang" based on TCM theory. Yin-Yang theory is a kind of logic which views things as a whole. The theory is based on two components: Yin and Yang, which are neither materials nor energy. They combine in a complementary manner and form a method for explaining relationships between objects. Gradually, this logic was developed into a system of thought that was applied to other areas. Traditional Chinese Medicine is an example of one area where the theory is used to understand complicated relationships in the body. Usually, Yang is associated with functional aspect of the body and has more energetic qualities, for example, expanding, heat, progressing, active and hyper-functioning states. Yin, on the other hand, is associated with the physical form and has less energetic qualities such as stillness, contracting, cold, degenerating, latent and under-functioning states. We have been studying CRS treatments with CHM for decades. The formulation of Zhu-yuan decoction (ZYD) was developed for postoperative treatment of CRS in the Eye and Ear, Nose, and Throat Hospital of Fudan University in the 1980s. In this study, we aimed to confirm the efficacy and safety of ZYD in patients after FESS. The diagnosis of CRS was based on a history of RS, the nasal endoscopy findings, and a CT scan. Duration of disease was quantified by continuous symptoms for at least 12 consecutive weeks. The diagnosis of CRS without nasal polyps (CRSwNP) was based on standard criteria issued in the 2012 European Position Paper on Rhinosinusitis and Nasal Polyps guidelines. 9 Any patient who had a history of immunodeficiency or systemic disease was excluded from the study. ZYD was prepared with Huoxiang (Herba Agastaches Rugosa) 9 g, Chenpi (Pericarpium Citri Reticulatae) 9 g, Huangqi (Radix Astragali Mongolici) 30 g, Yiyiren (Semen Coicis) 30 g, Zaojiaoci (Spina Gleditsiae) 12 g, Tianhuafen (Radix Trichosanthis) 12 g, Chuanxiong (Rhizoma Chuanxiong) 9 g, Qiyeyizhihuagen (Rhizoma Paridis) 9 g, Jiegeng (Radix Platycodi) 4.5 g, and Gancao (Radix Glycyrrhizae) 3 g.
MATERIALS AND METHODS

Criteria of diagnosis and inclusion
Treatments
A total of 106 patients met the eligibility criteria and were randomized into two groups: 55 received INC, and 51 were given CHM. After surgery, patients in the CHM group received ZYD. The Chinese medicinal materials were purchased and decocted by the pharmaceutical department. The decoction was taken orally once per day (100 mL). Patients in the INC group received a 3-month course of fluticasone propionate -100 g (2 sprays) to each side of the nose once dailyand were examined. Patients were followed up at 4, 8, and 12 weeks after FESS. They were asked not to use other medications, including antihistamines and systemic steroids, and underwent endoscopic debridement at each follow-up during the study period.
Measurement
Symptom score was assessed using a 10-point visual analog scale (VAS) for the following symptoms: nasal obstruction, nasal discharge (anterior and posterior), headache, facial pain, and olfactory disturbance. These scores were then added to give a total symptom score, with a maximum score of 50. The nasal cavities were examined with a nasal endoscope by the senior investigator. The presence or absence of discharge, swelling, and polyps, particularly in the middle meatus and olfactory cleft, was noted. Endoscopic scoring was performed per the Lanza-Kennedy system (discharge: 0 = no discharge; 1 = clear thin discharge; 2 = thick purulent discharge; swelling: 0 = no swelling; 1 = mild swelling; 2 = severe swelling; polyps: 0 = no polyp; 1 = only in the middle nasal meatus; 2 = exceeding the middle nasal meatus). 10 Each side was graded separately, and the scores from each side were then added to determine the overall endoscopy score. CT scans were performed pre-and post-operatively and scored according to the Lund-Mackay system. 11 Each sinus (maxillary, frontal, anterior ethmoid, posterior ethmoid, and sphenoid) was scored 0 (no opacification), 1 (partial opacification), or 2 (complete opacification). The ostiomeatal complex was scored 0 (no opacification), 1 (partial opacification), or 2 (opacification). The right and left sides were scored separately, and the scores were added together, giving a maximum possible overall score of 24. Any score of ≥ 1 was defined as abnormal. Safety analyses included whole blood count, liver function, and renal function before and after treatment. Participants were also asked to report any adverse events after receiving treatment. The sample size calculation was based on previous studies on CHM in post-FESS management. 12 
Statistical analysis
Statistical analyses were performed with SPSS for Windows, version 13.0 (SPSS, Inc., Chicago, IL, USA). The data are expressed as the means ± standard deviation ( x ± s). T Pearson χ 2 test, Mann-Whitney U test, and Wilcoxon signed-rank test were performed to analyze the differences between groups. The VAS, endoscopy, CT scores were compared before and after treatment by Mann-Whitney U test. P < 0.05 was the level of statistical significance.
RESULTS
A total of 106 patients met the study eligibility criteria and were randomized to receive INC (n = 55) or CHM (n = 51). Of the 106 subjects, 4 were excluded, because different diseases were diagnosed in the pathological examination of the surgical specimens after FESS. Three only received 4 weeks of treatment and were lost to follow-up, and 8 completed 8 weeks of treatment but did not return for the last follow-up; 6 patients were lost to follow-up at 12 weeks. Ultimately, 85 patients completed the study: 44 in the INC group and 41 in the CHM group. There were 30 male patients and 14 female patients in the INC group, versus 25 male and 16 female patients in the CHM group. The baseline characteristics of the participants are summarized in Table 1 Li J et al. / Research Article differences in gender or age between groups (P = 0.490 and 0.428, respectively). In addition, no significant differences were observed between groups in terms of pre-FESS VAS, endoscopy, and CT scores (Table 1) . Table 2 shows the post-FESS evaluation results for all patients. There were no significant differences in postoperative VAS, endoscopy, or CT scores between groups. Moreover, the VAS, endoscopy, and CT scores decreased significantly at 4, 8, and 12 weeks post-FESS in both groups compared with baseline values (Figures  2, 3) .
The rates of patients who were lost to follow-up were similar between groups: 20.5% (INC) and 19.5% (CHM). There were no significant abnormalities in liver or renal function in either group. No fatalities or major adverse events occurred during the trial.
DISCUSSION
In this trial, we evaluated the efficacy and safety of ZYD combined with FESS in patients with CRS. This treatment was safe, with no severe adverse reactions. 16 The most common side effect was liver toxicity. 17 Our results suggest that ZYD, in combination with surgery, can lower VAS, nasal endoscopy, and CT scores and has the same efficacy and safety profile as INC in post-FESS management. There were no liver or renal functional lesion in the trial. We are hopeful that this trial will support that ZYD can be used as an effective and safe treatment option for postoperative care in patients with CRS. TCM is one of the most popular alternative, complementary therapies worldwide. Herbal medicine is a major aspect of TCM, which focuses on restoring balance by nourishing the body. The herbal medicine has wide application and covers nearly every disease known in China. [18] [19] [20] It is becoming a prominent option in otorhinolaryngology, in which its use in the treatment of sinusitis, tinnitus, deafness, and Meniere disease is growing. Despite the general awareness of TCM, the literature relating specifically to otorhinolaryngology is relatively scarce. 21 Traditional herbal medicine has a promising role in post-FESS care, because some herbs have anti-in fl ammatory andimmunomodulating properties. 22, 23 Herbs have been used as adjuvant treatment with nasal steroids and oral antibiotics for post-FESS management in Asian countries, especially China. In Chinese medicine, the nasal sinus is termed "bi yuan," and "Zhu-Yuan" refers to the formulation that promotes the excretion of discharge from sinuses. Agastacherugosa, which is the main constituent of ZYD, has anti-inflammatory and antifungal effects. 24, 25 Pericarpium is a widely planted and consumed species in southern China with various therapeutic properties, reducing fevers and asthma, stimulating appetite, and enhancing immune system function. 26 In pharmacological studies, astragalushas shown anti-inflammatory, immunostimulatory, antioxidative, anticancer, antidiabetic, cardioprotective, hepatoprotective, and antiviral activities. 27 Adlay is a grass crop that has long been used in TCM and as a food supplement in China for the treatment of warts, chapped skin, rheumatism, neuralgia, and inflammatory and neoplastic diseases. 28 Other ingredients in ZYD promote the drainage of pus in the sinuses in CHM. The whole formulation of ZYD treats Chinese medicine syndrome -phlegm and heat obstructing the sinus -which is one of the most common syndromes associated with CRS, according to the balance theory of TCM. Notes: the baseline characteristics of the participants are summarized. There were no significant differences in gender and age among the two groups (P = 0.490 and 0.428, respectively). In addition, no significant differences were identified between CHM and INC group in terms of pre-FESS VAS scores, endoscopic sores and CT scores. This study has several limitations. It lasted only 12 weeks, and its long-term effects still need to be confirmed. Additionally, in actual clinical practice, ZYD is often combined with other pharmacological treatment, and we did not study its mechanism of action in detail. Therefore, future studies that take place over longer periods and study the combined effects of CHM and pharmacological agents might be useful to determine the efficacy of ZYD, and the mechanism underpinning the effects of ZYD must also be studied further. In conclusion, ZYD has similar efficacy and safety compared with intranasal cortisone. ZYD is a promising alternative treatment option for postoperative patients with CRS. 
